Physician profile
Daniel J Green
NPI 1285637181
$686.47
in general payments reported to CMS, 2019-2025
13 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $43.48 · 2021: $43.14 · 2022: $59.52 · 2023: $177 · 2024: $81.72 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376 · Entertainment: $14.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.88 |
| Entertainment | $14.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $219.73 | 2019-2025 | Hydrus Microstent, Tryptyr, Rocklatan |
| Novartis Pharmaceuticals Corporation | $133.69 | 2019-2023 | |
| Abbvie INC. | $73.56 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $45.90 | 2024 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $41.66 | 2022-2023 | Acthar |
| Thea Pharma INC. | $38.76 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $24.90 | 2023 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.90 | 2019 | |
| Amgen INC. | $22.27 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $18.73 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $15.45 | 2025 | Tecnis Iol |
| Optos, INC. | $14.22 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.